AstraZeneca may have included outdated information from its COVID-19 vaccine clinical trial, the Data and Safety Monitoring Board said late Monday. The outdated information may have provided an ...

If the Phase III trials of the oral GLP-1RA are successful, AstraZeneca is set to join a fast-growing market.

I'm initiating coverage on AstraZeneca (AZN) and setting it at a "Strong Buy" rating. The reason why is because the company was able to report massive growth in revenue in Q1 of 2026. During this ...

AstraZeneca Plc on Monday reported Phase 3 EMERALD-3 trial results showing that its immunotherapy-based STRIDE regimen, when ...